Background: Long-QT syndrome (LQTS), a cardiac arrhythmia disorder with variable phenotype, often results in devastating outcomes, including sudden cardiac death. Variable expression, independently from the primary diseasecausing mutation, can partly be explained by genetic modifiers. This study investigates variants in a known LQTScausative gene, AKAP9, for potential LQTS-type 1-modifying effects.Methods and Results: Members of a South African LQTS-type 1 founder population (181 noncarriers and 168 mutation carriers) carrying the identical-by-descent KCNQ1 p.Ala341Val (A341V) mutation were evaluated for modifying effects of AKAP9 variants on heart rate-corrected QT interval (QTc), cardiac events, and disease severity. Tag single nucleotide polymorphisms in AKAP9 rs11772585, rs7808587, rs2282972, and rs2961024 (order, 5'-3'positive strand) were genotyped. Associations between phenotypic traits and alleles, genotypes, and haplotypes were statistically assessed, adjusting for the degree of relatedness and confounding variables. The rs2961024 GG genotype, always represented by CGCG haplotype homozygotes, revealed an age-dependent heart rate-corrected QT interval increase (1% per additional 10 years) irrespective of A341V mutation status (P=0.006). The rs11772585 T allele, found uniquely in the TACT haplotype, more than doubled (218%) the risk of cardiac events (P=0.002) in the presence of A341V; additionally, it increased disease severity (P=0.025). The rs7808587 GG genotype was associated with a 74% increase in cardiac event risk (P=0.046), whereas the rs2282972 T allele, predominantly represented by the CATT haplotype, decreased risk by 53% (P=0.001).Conclusions: AKAP9 has been identified as an LQTS-type 1-modifying gene. Variants investigated altered heart rate-corrected QT interval irrespective of mutation status, as well as cardiac event risk, and disease severity, in mutation carriers.

de Villiers, C., van der Merwe, L., Crotti, L., Goosen, A., George, A., Schwartz, P., et al. (2014). AKAP9 is a genetic modifier of congenital long-QT syndrome type 1. CIRCULATION, CARDIOVASCULAR GENETICS, 7(5), 599-606 [10.1161/CIRCGENETICS.113.000580].

AKAP9 is a genetic modifier of congenital long-QT syndrome type 1

Crotti, L.;
2014

Abstract

Background: Long-QT syndrome (LQTS), a cardiac arrhythmia disorder with variable phenotype, often results in devastating outcomes, including sudden cardiac death. Variable expression, independently from the primary diseasecausing mutation, can partly be explained by genetic modifiers. This study investigates variants in a known LQTScausative gene, AKAP9, for potential LQTS-type 1-modifying effects.Methods and Results: Members of a South African LQTS-type 1 founder population (181 noncarriers and 168 mutation carriers) carrying the identical-by-descent KCNQ1 p.Ala341Val (A341V) mutation were evaluated for modifying effects of AKAP9 variants on heart rate-corrected QT interval (QTc), cardiac events, and disease severity. Tag single nucleotide polymorphisms in AKAP9 rs11772585, rs7808587, rs2282972, and rs2961024 (order, 5'-3'positive strand) were genotyped. Associations between phenotypic traits and alleles, genotypes, and haplotypes were statistically assessed, adjusting for the degree of relatedness and confounding variables. The rs2961024 GG genotype, always represented by CGCG haplotype homozygotes, revealed an age-dependent heart rate-corrected QT interval increase (1% per additional 10 years) irrespective of A341V mutation status (P=0.006). The rs11772585 T allele, found uniquely in the TACT haplotype, more than doubled (218%) the risk of cardiac events (P=0.002) in the presence of A341V; additionally, it increased disease severity (P=0.025). The rs7808587 GG genotype was associated with a 74% increase in cardiac event risk (P=0.046), whereas the rs2282972 T allele, predominantly represented by the CATT haplotype, decreased risk by 53% (P=0.001).Conclusions: AKAP9 has been identified as an LQTS-type 1-modifying gene. Variants investigated altered heart rate-corrected QT interval irrespective of mutation status, as well as cardiac event risk, and disease severity, in mutation carriers.
Articolo in rivista - Articolo scientifico
AKAP9; KCNQ1; arrhythmia; long-QT syndrome
English
2014
2014
7
5
599
606
reserved
de Villiers, C., van der Merwe, L., Crotti, L., Goosen, A., George, A., Schwartz, P., et al. (2014). AKAP9 is a genetic modifier of congenital long-QT syndrome type 1. CIRCULATION, CARDIOVASCULAR GENETICS, 7(5), 599-606 [10.1161/CIRCGENETICS.113.000580].
File in questo prodotto:
File Dimensione Formato  
de Villiers 2014 Circ Card Gen.pdf

Solo gestori archivio

Dimensione 717.23 kB
Formato Adobe PDF
717.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/182043
Citazioni
  • Scopus 54
  • ???jsp.display-item.citation.isi??? 47
Social impact